Related Experiment Video
Updated: Jul 7, 2026
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
Janka Koschack1, Martin Scherer, Claus Lüers
1Department of General Practice, Georg-August-University Göttingen, Germany. jkoscha@gwdg.de
Insights
Clinical assessment is as effective as N-terminal pro-brain natriuretic peptide (NT-proBNP) testing for ruling out left ventricular systolic dysfunction in at-risk patients. Family physicians can rely on clinical information for diagnosis, potentially reducing unnecessary echocardiography referrals.
Area of Science:
- Cardiology
- Primary Care Medicine
- Diagnostic Testing
Background:
- Screening for left ventricular systolic dysfunction (LVSD) in primary care may reduce echocardiography referrals.
- The utility and cost-effectiveness of natriuretic peptide testing in primary care remain debated.
Purpose of the Study:
- To evaluate the diagnostic power of N-terminal pro-brain natriuretic peptide (NT-proBNP) versus a clinical risk score in ruling out LVSD in primary care patients.
- To compare the effectiveness of NT-proBNP testing with clinical assessment for LVSD diagnosis.
Main Methods:
- Collected NT-proBNP levels, clinical data, and echocardiographic findings from 542 at-risk family practice patients.
- Developed a clinical risk score using logistic regression based on easily acquired clinical information.
- Assessed the diagnostic power (AUC, sensitivity, specificity) of both NT-proBNP and the clinical risk score.
Main Results:
- Both NT-proBNP and the clinical risk score demonstrated excellent power in ruling out LVSD.
- The clinical risk score (AUC 0.85) showed higher specificity (0.64) compared to NT-proBNP (AUC 0.83, specificity 0.46).
- The clinical risk score resulted in significantly fewer misclassifications (55) than NT-proBNP (148).
Conclusions:
- Clinical information evaluation is as effective as NT-proBNP testing for ruling out LVSD in at-risk primary care patients.
- Family physicians may rely on clinical information for diagnosis, pending confirmation in larger studies.
- This approach could optimize diagnostic pathways and resource utilization in primary care.
Background:
Screening of primary care patients at risk for left ventricular systolic dysfunction by a simple blood-test might reduce referral rates for echocardiography. Whether or not natriuretic peptide testing is a useful and cost-effective diagnostic instrument in primary care settings, however, is still a matter of debate.
Methods:
N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, clinical information, and echocardiographic data of left ventricular systolic function were collected in 542 family practice patients with at least one cardiovascular risk factor. We determined the diagnostic power of the NT-proBNP assessment in ruling out left ventricular systolic dysfunction and compared it to a risk score derived from a logistic regression model of easily acquired clinical information.
Results:
23 of 542 patients showed left ventricular systolic dysfunction. Both NT-proBNP and the clinical risk score consisting of dyspnea at exertion and ankle swelling, coronary artery disease and diuretic treatment showed excellent diagnostic power for ruling out left ventricular systolic dysfunction. AUC of NT-proBNP was 0.83 (95% CI, 0.75 to 0.92) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.46 (95% CI, 0.41 to 0.50). AUC of the clinical risk score was 0.85 (95% CI, 0.79 to 0.91) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.64 (95% CI, 0.59 to 0.67). 148 misclassifications using NT-proBNP and 55 using the clinical risk score revealed a significant difference (McNemar test; p < 0.001) that was based on the higher specificity of the clinical risk score.
Conclusion:
The evaluation of clinical information is at least as effective as NT-proBNP testing in ruling out left ventricular systolic dysfunction in family practice patients at risk. If these results are confirmed in larger cohorts and in different samples, family physicians should be encouraged to rely on the diagnostic power of the clinical information from their patients.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
01:22Aortic Regurgitation II: Clinical Features and Diagnostic Tests
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests